missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ KHDRBS3 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5115466
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total KHDRBS3.
As a RNA-binding protein, KHDRBS3 plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. KHDRBS3 may play a role as a negative regulator of cell growth. It inhibits cell proliferation and involved in splice site selection of vascular endothelial growth factor. It induces an increased concentration-dependent incorporation of exon in CD44 pre-mRNA by direct binding to purine-rich exonic enhancer. RNA-binding abilities are down-regulated by tyrosine kinase PTK6. It also involved in post-transcriptional regulation of HIV-1 gene expression.
Specifications
| KHDRBS3 | |
| Polyclonal | |
| Unconjugated | |
| Khdrbs3 | |
| Etle; etoile; etoile, Sam68-like protein SLM-2; KH domain containing, RNA binding, signal transduction associated 3; KH domain-containing, RNA-binding, signal transduction-associated protein 3; KH RNA binding domain containing, signal transduction associated 3; KHDRBS3; RNA-binding protein Etoile; RNA-binding protein T-Star; rSLM-2; SALP; Sam68-like mammalian protein 2; Sam68-like phosphotyrosine protein; Sam68-like phosphotyrosine protein, T-STAR; SLM2; SLM-2; TSTAR; T-STAR | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 10656, 13992, 64015 | |
| -20°C | |
| Liquid |
| Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide | |
| O75525, Q9JLP1, Q9R226 | |
| Khdrbs3 | |
| A synthesized peptide derived from human KHDRBS3(Accession O75525), corresponding to amino acid residues A246-Q296. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction